Nonalcoholic Steatohepatitis
Resmetirom for Nonalcoholic Steatohepatitis (NASH)
Resmetirom ( Rezdiffra ) is set to become the first medication approved for treating nonalcoholic steatohepatitis (NASH) with fibrosis in adults . About 5% of adults in the US have NASH. You will start to hear NASH called metabolic dysfunction-associated steatohepatitis (MASH) to reflect its link with cardiometabolic risk factors (diabetes, dyslipidemia, obesity, etc…
قراءة المزيد
Vitamin-E
Guide to manage NONalcoholic fatty liver disease
As a clinical pharmacist, you will see more focus on managing nonalcoholic fatty liver disease (NAFLD) , partly due to new guidelines. It’s being called a “sleeper epidemic” About 1 in 4 patients have this steatosis, but most don’t have symptoms. NAFLD often goes hand in hand with cardiovascular (CV) risk factors, such as insulin resistance or diabetes , obesity an…
قراءة المزيد
Pioglitazone
Consider Actos for NASH patients
As a hospital pharmacist, you will see more nonalcoholic fatty liver disease (NAFLD) . According to studies, up to 100 million Americans have this buildup of fat in the liver. It often goes hand in hand with obesity , dyslipidemia , insulin resistance , and diabetes . About 20% of patients with NAFLD have nonalcoholic steatohepatitis (NASH) , the mo…
قراءة المزيد
Vitamin-E
Overview of nonalcoholic fatty liver disease (NAFLD)
N onalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. Severity ranges from mild disease with steatosis (buildup of fat in the liver) to more severe disease with inflammation and hepatocyte (liver cell) injury known as nonalcoholic steatohepatitis (NASH). NASH is projected to be the leading liver transplant indication by the …
قراءة المزيد
Social Plugin